Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReTreatment Trial of Ruxolitinib in Myelofibrosis After Treatment Interruption
2013-004816-22Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more, sponsored by Novartis. Primary endpoint: Proportion of patients achieving ≥20% reduction in spleen volume at Week 24. Started Apr 2014; status: terminated.
02
Drugs
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2013-004816-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004816-22.